RxDoctor Payments Data

Charles Anderson, MD

Internal Medicine · Naples, FLNPI 1245282797

Payments from drug & device makers

$1,101in general payments, 2019–2025

Across 13 payments — averaging $84.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$345
  • Amgen$191
  • Pfizer$117
  • Merck$112
  • Novartis$110
  • Lilly USA, LLC$89
  • plus $137 from 3 others

What the payments were for

  • Food & beverage$1,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$345
Amgen2$191
Pfizer1$117
Merck1$112
Novartis1$110
Lilly USA, LLC2$89
AstraZeneca1$64
Sanofi Pasteur Inc.1$52
Abbott1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,101 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$242,426
Medicare patients
465
Services billed
5,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$129,612
OzempicSemaglutide58$70,424
JanuviaSitagliptin Phosphate32$39,526
JardianceEmpagliflozin34$39,316
DescovyEmtricitabine/Tenofov Alafenam16$34,532
XareltoRivaroxaban27$34,452
TrulicityDulaglutide12$17,950
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$17,601
EntrestoSacubitril/Valsartan16$15,189
Tresiba Flextouch U-200Insulin Degludec11$14,148
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$12,269
Tresiba Flextouch U-100Insulin Degludec18$10,872
SynthroidLevothyroxine Sodium44$4,983
Atorvastatin Calcium396$3,680
Levothyroxine Sodium353$3,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$117$129,612104 claims
Novo NordiskOzempic$345$70,42458 claims
MerckJanuvia$112$39,52632 claims
Lilly USA, LLCTrulicity$89$17,95012 claims
NovartisEntresto$110$15,18916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →